Renoprotective effects of GLP1R agonists and SGLT2 inhibitors
- New data from the LEADER trial show that the glucagon-like peptide 1 receptor agonist liraglutide protects against diabetic nephropathy in patients with type 2 diabetes mellitus. The renoprotective efficacy of liraglutide is not, however, as great as that reported for the sodium-glucose cotransporter 2 inhibitor emplagiflozin in the EMPA-REG OUTCOME trial.
| Author details: | Berthold HocherORCiDGND, Oleg TsuprykovGND |
|---|---|
| DOI: | https://doi.org/10.1038/nrneph.2017.140 |
| ISSN: | 1759-5061 |
| ISSN: | 1759-507X |
| Pubmed ID: | https://pubmed.ncbi.nlm.nih.gov/28989173 |
| Title of parent work (English): | Nature reviews nephroloy |
| Publisher: | Nature Publ. Group |
| Place of publishing: | New York |
| Publication type: | Other |
| Language: | English |
| Date of first publication: | 2017/10/09 |
| Publication year: | 2017 |
| Release date: | 2021/02/08 |
| Volume: | 13 |
| Number of pages: | 2 |
| First page: | 728 |
| Last Page: | 729 |
| Funding institution: | Boehringer Ingelheim |
| Organizational units: | Mathematisch-Naturwissenschaftliche Fakultät / Institut für Ernährungswissenschaft |
| DDC classification: | 6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit |
| Peer review: | Referiert |
